We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+10.83%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.37B
AUM Growth
+$618M
Cap. Flow
+$498M
Cap. Flow %
7.82%
Top 10 Hldgs %
71.12%
Holding
53
New
7
Increased
13
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$224M
2
XLRN
Acceleron Pharma
XLRN
+$131M
3
FOLD
Amicus Therapeutics
FOLD
+$53.5M
4
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
5
NUVL
Nuvalent
NUVL
+$36.5M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$108M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$38.4M
3
RLMD icon
Relmada Therapeutics
RLMD
+$29.9M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$24.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$986M 15.49%
9,000,000
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$885M 13.89%
5,000,000
– –
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$688M 10.81%
4,000,000
+1,000,000
+33% +$131M
UTHR icon
4
United Therapeutics
UTHR
$26.1B
$554M 8.7%
3,000,000
– –
ASND icon
5
Ascendis Pharma A/S
ASND
$16.5B
$316M 4.96%
1,980,000
+80,000
+4% +$10.9M
ARGX icon
6
argenx
ARGX
$55.2B
$286M 4.49%
946,500
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.64B
$231M 3.63%
2,500,000
+100,000
+4% +$7.7M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.04B
$210M 3.29%
8,500,000
-600,000
-7% -$14.1M
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
$204M 3.2%
3,425,000
-650,000
-16% -$38.4M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$169M 2.65%
17,679,273
+5,229,273
+42% +$53.5M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$165M 2.59%
5,000,000
+3,994,770
+397% +$224M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$38.3B
$160M 2.52%
850,000
-150,000
-15% -$28.1M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.9B
$145M 2.28%
1,875,000
+225,000
+14% +$17.8M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$123B
$120M 1.89%
664,000
-126,000
-16% -$24.6M
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$115M 1.81%
7,100,000
+675,000
+11% +$7.35M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.6B
$114M 1.79%
1,425,000
– –
TRIL
17
DELISTED
Trillium Therapeutics Inc.
TRIL
$100M 1.57%
5,700,000
– –
PMVP icon
18
PMV Pharmaceuticals
PMVP
$57.1M
$87.2M 1.37%
2,925,000
+1,100,000
+60% +$35.1M
KURA icon
19
Kura Oncology
KURA
$793M
$74.9M 1.18%
4,000,000
-140,000
-3% -$2.64M
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$64.1M 1.01%
272,000
– –
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$1.82B
$61M 0.96%
3,311,434
– –
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.1B
$55.8M 0.88%
3,650,000
– –
WHWK
23
Whitehawk Therapeutics
WHWK
$181M
$53.7M 0.84%
1,829,402
+1,529,402
+510% +$46.6M
MNKD icon
24
MannKind Corp
MNKD
$1.19B
$38.3M 0.6%
8,800,000
+170,000
+2% +$766K
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$37.6M 0.59%
10,300,000
– –
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Avoro Capital Advisors held 53 positions worth $6.37B, up 11% from $5.75B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors deployed $498M of net new capital in Q3 2021, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Nuvalent: 1,257,671 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $38.4M trimmed.

  • Avoro Capital Advisors's largest Q3 2021 buy was Nuvalent: 1,257,671 shares worth $22.3M.
  • Avoro Capital Advisors added most to Apellis Pharmaceuticals in Q3 2021, an estimated $224M increase.
  • Avoro Capital Advisors's biggest Q3 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $38.4M.
  • Avoro Capital Advisors fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $108M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $6.37B portfolio in Q3 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 6 in Q3 2021.
  • Avoro Capital Advisors's portfolio value rose 11% quarter-over-quarter to $6.37B.

Based on Avoro Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.